Contact this trialFirst, we need to learn more about you.
SGLT2 Inhibitor
Licogliflozin +1 More for Non-alcoholic Fatty Liver Disease
Recruiting0 awardsPhase 2
Doral, Florida
This trial is testing a new combination therapy for NASH and comparing it to placebo. The trial is double-blind, meaning neither the patients nor the researchers will know who is receiving the active drug or the placebo.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.